	Mapping the Causal Landscape of Psoriasis: A Systematic Mendelian Randomization Evidence Synthesis and Development of the MR-PsO Atlas Platform. Exp Dermatol Lu JY, Zeng W, Wang K, Zhou J, Pan W, Fan Q, Yang Q, Liu M, Ren KF. PMID: 42157626 [PubMed - indexed for MEDLINE]
	Repair of radiographic joint damage in psoriatic arthritis: a cohort study. Rheumatology (Oxford) Haddad A, Kharouf F, Lee KA, Zou L, Pereira D, Cook RJ, Chandran V, Gladman DD. PMID: 42157419 [PubMed - as supplied by publisher]
	The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa-A Narrative Review. Dermatol Ther (Heidelb) Lewandowska JA, Owczarczyk-Saczonek A. PMID: 42156635 [PubMed - as supplied by publisher]
	Studying the expression levels of LncRNA-MEG3 and miR-147b in the serum of psoriasis patients with and without dyslipidemia. Sci Rep Kamel M, Marzouk RE, Shaker OG, Gameil MA, Amrousy YM, Farag E, Abdallah HM, Wagdy A, Mahdi L. PMID: 42156472 [PubMed - indexed for MEDLINE]
	Global Healthcare Study on Psoriasis (GHSP): cohort profile and first findings. BMJ Open Maul JT, Fröhlich F, Nielsen ML, Maul LV, Torres T, Thyssen J, Armstrong A, Oon HH, Ji M, Kang X, Valenzuela F, Romiti R, Carvalho AVE, Novoa F, Sousa M, Luz M, Guevara BEK, Doss N, Gisondi P, Chularojanamontri L, Kündig TM, Egeberg A, Thomsen SF, Didaskalu JA. PMID: 42156142 [PubMed - indexed for MEDLINE]
	High 12-month persistence and effectiveness of IL-23 inhibitors in psoriatic arthritis: a multicenter retrospective real-world study from Argentina. Rheumatol Int Garcia-Salinas R, Sommerfleck F, Benitez A, Dellepiane A, Estevez A, Fenucci M, Gomez G. PMID: 42154041 [PubMed - indexed for MEDLINE]
	Control of Inflammation and Sustained Improvements in Patient-Reported Outcomes in Patients With Psoriatic Arthritis: Bimekizumab Two-Year Results From Two Phase 3 Studies. ACR Open Rheumatol Gossec L, Tillett W, Coates LC, Mease PJ, de Wit M, Gladman DD, Orbai AM, Proft F, Ink B, Bajracharya R, Lambert J, Healy P, Husni ME. PMID: 42152504 [PubMed]
	Causality analysis of fatty acids, triglycerides and psoriasis based on Mendelian randomization. Medicine (Baltimore) Long J, Deng C, Huang M, Tang L, Li Q, Wang F, Lin Y. PMID: 42152394 [PubMed - indexed for MEDLINE]
	Cutaneous Manifestations in Psoriatic Arthritis: Phenotypes, Clinical Burden, and Therapeutic Implications. Rheumatol Ther Tsafis K, Skepastianos V, Skouvaklidou E, Deligeorgakis D, Boutel M, Kontonikola A, Papazoglou N, Fragoulis GE, Kougkas N. PMID: 42151579 [PubMed - as supplied by publisher]
	Psoriasis in skin of color: clinical presentation, diagnostic challenges, and therapeutic considerations. An Bras Dermatol Costa A, Romiti R. PMID: 42150334 [PubMed - as supplied by publisher]
	An update on the safety of biologics for the treatment of psoriasis. Expert Opin Drug Saf McGuirt V, Patel H, Davis M, Feldman S. PMID: 42149685 [PubMed - as supplied by publisher]
	Biotics: The Food Ingredients Supporting the Intestinal Microbiota and Immune System in Psoriasis. Nutr Rev De Biasi J, Giménez Bastida JA, Krupa-Kozak U. PMID: 42148824 [PubMed - as supplied by publisher]
	Mesenchymal stromal cell-derived extracellular vesicles (MSC-EVs) as a novel topical immunomodulatory therapy for psoriasis: bridging the therapeutic gap in moderate disease. Extracell Vesicles Circ Nucl Acids Tan TT, Tan KH, Lim SK. PMID: 42148284 [PubMed]
	Navigating renal safety in the biologic treatment of psoriasis: from immunologic mechanisms to clinical practice. Front Immunol Tang Z, Wu J, Dong M, Li C, Wang R. PMID: 42148093 [PubMed - indexed for MEDLINE]
	Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study. Psoriasis (Auckl) Mrowietz U, Sommer R, Reguiai Z, Gerdes S, Daudén E, Weger W, Maul JT, Naldi L, Ghislain PD, Laws PM, De Jong EMGJ, Mburu S, Koscielny V, Massana E, Sapena V, Domenech A, Kasujee I, Augustin M. PMID: 42146323 [PubMed]
	Improvements in Clinical and Patient-Reported Outcomes and Durability of Response With the Targeted Oral Peptide Icotrokinra in Adolescents With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the ICONIC-LEAD Randomized Controlled Trial. J Am Acad Dermatol Soung J, Lebwohl MG, Hebert A, Pink AE, Shi Y, Hong HC, Iaconangelo C, Miller-Kassamali M, Cafone J, DeKlotz CMC, Jiang J, Li S, Yang YW, Eichenfield L. PMID: 42144198 [PubMed - as supplied by publisher]
	Risankizumab versus Deucravacitinib in Adults With Moderate Plaque Psoriasis: 16-Week Results from the Phase 4 IMMpactful Trial. Dermatol Ther (Heidelb) Magnolo N, Soung J, Frew J, Costanzo A, Ruiz-Santiago H, Eyerich K, Llamas-Velasco M, Bukhalo M, Sivamani RK, Moore A, Wu T, Xie J, Patel M, Ashley D, Kaplan B, Stakias V, Espaillat R, Warren RB. PMID: 42143644 [PubMed - as supplied by publisher]
	Musculoskeletal and nail ultrasound findings in children with psoriasis: a case-control study. Pediatr Rheumatol Online J Nedorezov L, Avar-Aydin PO, Ting TV, Bayart C, Cassedy A, Vega-Fernandez P. PMID: 42143389 [PubMed - as supplied by publisher]
	Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial. Dermatol Ther (Heidelb) Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W, Winkelman W, Gooderham MJ. PMID: 42143206 [PubMed - as supplied by publisher]
	Inflammatory bowel disease and psoriasis as causal drivers of psychiatric disorders: A two-stage Mendelian randomization study grounded in the gut-brain-skin axis. J Affect Disord Li H, Guo Y, Zhang Z, Yang J, Li Y, Fu X, Yang S. PMID: 42142759 [PubMed - as supplied by publisher]

Articles 1 - 20 / 27936

Page 1 of 1397



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy